sertraline (Zoloft)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Posttraumatic Stress Disorder
Conditions
Posttraumatic Stress Disorder
Trial Timeline
Aug 1, 2012 → Oct 1, 2012
NCT ID
NCT01607593About sertraline (Zoloft)
sertraline (Zoloft) is a pre-clinical stage product being developed by Pfizer for Posttraumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01607593. Target conditions include Posttraumatic Stress Disorder.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01607593 | Pre-clinical | Completed |
| NCT00179257 | Phase 3 | Completed |
Competing Products
8 competing products in Posttraumatic Stress Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Adjunctive asenapine | Merck | Approved | 85 |
| Ziprasidone | Pfizer | Approved | 84 |
| Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg | Brain Biotech | Phase 2 | 44 |
| High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis | Tilray | Phase 2 | 47 |
| Riluzole | Brain Biotech | Phase 1 | 25 |